News

Topical chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO, Harrow) resulted in less pain f following intravitreal injections in patients undergoing same-day bilateral intravitreal injections.

The Aug. 20-23 meeting in Monterey, California, offers CME across subspecialties alongside sessions on mentorship, career longevity, and research.

ZEISS CLINIC 360 is an all-in-one cloud and browser-based software platform designed to consolidate ophthalmic diagnostic and medical record data into a single, unified patient view.

Amy Zhang, MD, on the ergonomic habits and equipment changes that protect ophthalmic surgeons' careers long-term.

The FDA issued a recall notice for an eye drop designed to relieve ocular redness, itching, burning, and watery eyes. The Class II recall alerts consumers and physicians to possible temporary or reversible health effects, but serious harm is unlikely.

Neel S. Vaidya, MD, MPH, MBA, on why keratoconus can progress aggressively in children and teens—and how early topographic screening and prompt crosslinking protect long-term vision.

Host Deborah G. Ristvedt, DO, welcomes Dr. Berdahl to discuss the formative experiences, entrepreneurial drive, and personal philosophy that have shaped his career as a surgeon, innovator, and mentor.

AI accelerates retina trials and imaging insights, boosts screening access, and raises urgent questions on regulation, privacy, and equity.

The Jack McGovern Coats' Disease Foundation has announced the initiation of new research to develop the first validated animal model of Coats' Disease, a rare eye disorder that primarily affects children.

Approach centers on pressure-free messaging and optometric education

Patient enrollment is complete in a phase 3 registrational, or pivotal, trial to evaluate OPGx-LCA5, a gene therapy that is under investigation for treating Leber congenital amaurosis type 5-associated inherited retinal disease.

Two investigational pipeline therapies take aim at the root causes of dry eye disease

Noha Ekdawi, MD, FAAP, explains why pediatric myopia demands individualized, progression-based management. She details how they sequence spectacle defocus lenses, low-dose atropine, and specialty contacts; drive long-term adherence; and frame lifetime risk for parents without causing alarm.

Waste, cost, and carbon are converging to reshape how cataract centers choose instruments.

Ahead of his November 10, 2026, start date, the incoming Duke ophthalmology chair shares his vision for research, training, and the integration of AI and data science.

Sight Sciences' newest MIGS device gains FDA clearance for single-pass canaloplasty and trabeculotomy in open-angle glaucoma.

The trial is evaluating the company’s orally administered synthetic cannabinoid, ART27.13

Harrow will acquire Tyrvaya, the only FDA-approved nasal spray for dry eye disease, from Viatris for up to $100 million, complementing its cyclosporine product Vevye.

Capsulotomy size may not be refractive neutral: a larger opening shifted the IOL about 120 µm posteriorly in thin lenses and anteriorly in thick ones in a paired-eye study.

Private practice fellowships sharpen cataract and refractive skills with high volume, new tech, and hands-on practice management mentorship.

This article discusses the current treatments being investigated during the first half of 2026.

Wet AMD gains a new FDA-approved therapy as retina, glaucoma, and dry eye pipelines surge—plus AI, devices, and workforce trends reshaping care.

In part 2 of a 2-part article, Arun C. Gulani, MD, walks through the 4 patient types of the Gulani classification of refractive lens exchange, from primary vision enhancement to staged vision engineering, and explains why outcomes depend on treating the eye as a complete optical system rather than on the implant alone.

The annual Best Hospitals report from US News & World Report compares more than 4500 hospitals across 14 specialties and 22 procedures and conditions.

Andrew G. Lee, MD, and Drew Carey, MD, discuss a study exploring whether these two conditions are really one disease—and what that means for long-term treatment.

The first half of 2026 turned on inherited pediatric eye disease, with 2 gene therapy programs advancing toward registration and a high-profile complete response letter in a childhood-onset optic neuropathy.

Retina specialists Baruch D. Kuppermann, MD, PhD, and Firas M. Rahhal, MD, discuss the significance of bevacizumab-vikg's approval for wet AMD and its impact on physicians and patients.

An investigational drug has shown positive activity against metastatic uveal melanoma in a phase 1 study.